J
Jakob Passweg
Researcher at University Hospital of Basel
Publications - 656
Citations - 31351
Jakob Passweg is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 86, co-authored 591 publications receiving 27282 citations. Previous affiliations of Jakob Passweg include University of St. Gallen & University of Basel.
Papers
More filters
Journal ArticleDOI
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Robert Kralovics,Francesco Passamonti,Andreas Buser,Soon Siong Teo,Ralph Tiedt,Jakob Passweg,André Tichelli,Mario Cazzola,Radek C. Skoda +8 more
TL;DR: Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages and a high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
Journal ArticleDOI
Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant Recipients
Hans H. Hirsch,Wendy Knowles,Michael Dickenmann,Jakob Passweg,Thomas Klimkait,Michael J. Mihatsch,Jürg Steiger +6 more
TL;DR: BKV nephropathy in renal-transplant recipients represents a secondary infection associated with rejection and its treatment in most cases and could be monitored by measuring the viral load in plasma.
Journal ArticleDOI
Solid Cancers after Bone Marrow Transplantation
Rochelle E. Curtis,Philip A. Rowlings,H. Joachim Deeg,Donna A. Shriner,Gérard Socié,Lois B. Travis,Mary M. Horowitz,Robert P. Witherspoon,Robert N. Hoover,Kathleen A. Sobocinski,Joseph F. Fraumeni,John D. Boice,H. Gary Schoch,George E. Sale,Rainer Storb,William D. Travis,Hans-Jochem Kolb,Robert Peter Gale,Jakob Passweg +18 more
TL;DR: The trend toward an increased risk over time after transplantation and the greater risk among younger patients indicate the need for life-long surveillance.
Journal ArticleDOI
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
Gérard Socié,Judith A. Veum Stone,John R. Wingard,Daniel J. Weisdorf,Henslee-Downey Pj,Christopher Bredeson,Jean-Yves Cahn,Jakob Passweg,Philip A. Rowlings,H. Schouten,Hans-Jochem Kolb,John P. Klein +11 more
TL;DR: Among patients who underwent transplantation for aplastic anemia, the risk of death by the sixth year after transplantation did not differ significantly from the general population, and the probability of living for five more years was 89 percent.
Journal ArticleDOI
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Mojca Jongen-Lavrencic,Tim Grob,Diana Hanekamp,François G. Kavelaars,Adil Al Hinai,Annelieke Zeilemaker,Claudia A.J. Erpelinck-Verschueren,Patrycja L Gradowska,Rosa Meijer,Jacqueline Cloos,Bart J. Biemond,Carlos Graux,Marinus van Marwijk Kooy,Markus G. Manz,Thomas Pabst,Jakob Passweg,Violaine Havelange,Gert J. Ossenkoppele,Mathijs A. Sanders,Gerrit Jan Schuurhuis,Bob Löwenberg,Peter J. M. Valk +21 more
TL;DR: The detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates, but the detection of persistent mutations that are associated with clonal hematopoiesis did not have such prognosticvalue within a 4‐year time frame.